Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29-09-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
PTAB upholds Biogen’s MS drug patent
23-03-2017
PictureDesignSwiss / Shutterstock.com
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera (dimethyl fumarate) should remain invalid because the matter had already been resolved by another court.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Biogen, biotechnology, multiple-sclerosis, patent, US federal judge, generics, Mylan, DMF, Tecfidera, US District Court for the District of Delaware
